A safety and efficacy study of eltrombopag in older than 65 years old primary immune thrombocytopenia patients: Spanish Eltrombopag ITP Registry trial.
Latest Information Update: 12 Sep 2016
Price :
$35 *
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- 12 Sep 2016 New trial record